Omeros Corporation Reports Second Quarter 2026 Financial Results
Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2026, which include: Second Quarter and Recent Highlights YARTEMLEA, the first and only approved treatment for stem cell transplant-associated...